Monoclonal Antibody Therapy at Montefiore

If you have COVID-19, you may be at high-risk for severe symptoms. Talk to your doctor to see if you are eligible for monoclonal antibody treatment, based on your age, the length of your symptoms, and existing medical conditions.

What is monoclonal antibody therapy?
Image
Monoclonal Antibody

Monoclonal antibodies are created in a lab and function like naturally occurring antibodies, fighting infections before they spread. Studies show that when monoclonal antibodies are given intravenously to high-risk people diagnosed early with COVID-19, it can prevent them from experiencing severe symptoms that lead to hospitalizations.

Montefiore has been offering monoclonal antibody treatment to patients since December 2020 in our Montefiore’s Bronx Emergency Departments. Since then, Montefiore opened an infusion suite – now the main location for this therapy – and is partnering with local nursing homes to treat their residents.

There are multiple monoclonal antibody therapies available, which have been authorized by the Food and Drug Administration. We are now offering the Regeneron combination of Casirivimab and Imdevimab, which has also proved effective in treating COVID-19 variances.

How is monoclonal antibody therapy given?

The monoclonal antibody treatment is given using IV therapy, administered through a vein in the arm, for about an hour. Patients are evaluated by a nurse practitioner and then monitored for any allergic reactions, which are extremely rare. The appointment takes about three hours to complete; afterward, patients receive a follow-up phone visit. A few weeks later, a telehealth appointment is completed with an infectious disease doctor who reviews recovery and symptoms.

Am I eligible for monoclonal antibody therapy?

To qualify, you must have tested positive for COVID-19 recently; have mild to moderate symptoms that are managed without oxygen support; and fall into one of the high-risk categories below. Monoclonal antibody treatment is not for patients who are hospitalized.

You're eligible to be treated with the monoclonal antibody if you are:

65 years of age or older

55 years or older with any of the following:

  • Heart disease
  • High blood pressure
  • COPD/chronic respiratory disease, including asthma.

Any adult with any of the following:

  • Obesity (a body mass index [BMI] of 35 or higher)
  • Diabetes (Type 1 or Type 2)
  • Chronic kidney disease
  • A weakened immune system
  • You're taking medicine that weakens your immune system.

12 to 17 years of age and at least 40 kg (88 pounds) with any of the following:

  • Obesity (a BMI greater than or equal to 85 percent of patients of the same age and gender)
  • Regularly uses medical technology such as a ventilator or feeding tube
  • Have a developmental condition like cerebral palsy
  • Sickle cell disease
  • Congenital or acquired heart disease
  • Asthma/chronic respiratory problems requiring daily medication for control.
How can I receive monoclonal antibody therapy?

To schedule an appointment, please call please call 1-844-444-CV19.

Location and Contact Information

1575 Blondell Ave, Suite 125, 2nd Floor
Bronx, NY 10461
718-405-8125
CovidAntibodies@montefiore.org
Business Hours: Monday - Friday 8:30am - 5:00pm

To schedule a consultation, please call 1-844-444-CV19.

Image
Priya Nori, MD

Longstanding inequities and chronic disease have led to high COVID-19 infection rates and significant risk of death in the Bronx. Now Bronx residents have a safe, evidence-based treatment that stops COVID-19 in its tracks and is preventing severe illness.

Priya Nori, MD
Infectious disease specialist and Director of the Antibiotic Stewardship Program at Montefiore, and Associate Professor of Medicine at Albert Einstein College of Medicine

Trusted Information Resources

Centers for Disease Control and Prevention

The leading national public health institute of the United States
 

NY.gov

For the latest COVID-19 guidelines and information from New York State 

World Health Organization

UN agency responsible for international public health